ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,881.63
-0.43%
Dow Jones
42,544.22
0.00%
US Dollar vs MXN
20.75223
-0.41%
Brent Oil
75.485
2.21%
Bitcoin
96,730.89
2.48%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Vanda Pharmaceuticals Inc (VNDA) Cotización

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

NASDAQ
4.79
0.01
(0.21%)
Cerrado 31 Diciembre 3:00PM
Delayed by 15 minutes
4.79
0.00
( 0.00% )
Pre Mercado: 6:23AM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
4.79
Postura de Compra
4.76
Postura de Venta
4.87
Volume Operado de la Acción
140
0.00 Rango del Día 0.00
3.46 Rango de 52 semanas 6.75
Capitalización de Mercado [m]
279.296M
Precio Anterior
4.79
Precio de Apertura
-
Hora
139
@
4.79
(formt)
Última hora de negociación
06:21:21
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
691,337
Acciones en circulación
58,308,144
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
111.40
Beneficio por acción (BPA)
0.04
turnover
192.64M
Beneficio neto
2.51M

Acerca de Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.vandapharma.com
Sede
Wilmington, Delaware, USA
Fundado
-
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was US$4.79. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of US$ 3.46 to US$ 6.75.

Vanda Pharmaceuticals currently has 58,308,144 shares in issue. The market capitalisation of Vanda Pharmaceuticals is US$279.30 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 111.40.

VNDA Últimas noticias

Más noticias

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera PR...

20 Diciembre 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

18 Noviembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

14 Noviembre 2024
Edgar (US Regulatory)

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences PR Newswire WASHINGTON, Nov. 12, 2024 WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc...

12 Noviembre 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 Noviembre 2024
Edgar (US Regulatory)

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire WASHINGTON, Nov. 6, 2024 Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial...

06 Noviembre 2024
PR Newswire (US)

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire WASHINGTON, Oct. 30, 2024 Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024...

30 Octubre 2024
PR Newswire (US)

Form 8-K - Current report

15 Octubre 2024
Edgar (US Regulatory)

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. PR Newswire WASHINGTON, Oct. 14, 2024 Board Has Determined That...

14 Octubre 2024
PR Newswire (US)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1004.794.94.71054239114.79476536CS
4-0.03-0.6224066390044.824.954.456839914.69900661CS
120.378.371040723984.425.5454.356913374.85962675CS
26-0.79-14.15770609325.586.3654.356352055.10320889CS
520.5914.04761904764.26.753.4612056654.95301083CS
156-10.98-69.625871908715.7716.9253.2958435846.25580411CS
260-11.81-71.144578313316.621.86273.2957201238.59060885CS

VNDA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Vanda Pharmaceuticals?
El precio actual de las acciones de Vanda Pharmaceuticals es US$ 4.79
¿Cuántas acciones de Vanda Pharmaceuticals están en circulación?
Vanda Pharmaceuticals tiene 58,308,144 acciones en circulación
¿Cuál es la capitalización de mercado de Vanda Pharmaceuticals?
La capitalización de mercado de Vanda Pharmaceuticals es USD 279.3M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Vanda Pharmaceuticals?
Vanda Pharmaceuticals ha negociado en un rango de US$ 3.46 a US$ 6.75 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Vanda Pharmaceuticals?
El ratio precio/beneficio de Vanda Pharmaceuticals es 111.4
¿Cuál es el ratio de efectivo a ventas de Vanda Pharmaceuticals?
El ratio de efectivo a ventas de Vanda Pharmaceuticals es 1.45
¿Cuál es la moneda de reporte de Vanda Pharmaceuticals?
Vanda Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Vanda Pharmaceuticals?
El último ingresos anual de Vanda Pharmaceuticals es USD 192.64M
¿Cuál es el último beneficio anual de Vanda Pharmaceuticals?
El último beneficio anual de Vanda Pharmaceuticals es USD 2.51M
¿Cuál es la dirección registrada de Vanda Pharmaceuticals?
La dirección registrada de Vanda Pharmaceuticals es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Vanda Pharmaceuticals?
La dirección del sitio web de Vanda Pharmaceuticals es www.vandapharma.com
¿En qué sector industrial opera Vanda Pharmaceuticals?
Vanda Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
RAINRain Enhancement Technologies Holdco Inc
 11.39
(841.32%)
260
REVBRevelation Biosciences Inc
US$ 1.12
(142.95%)
30.02M
CGBSCrown LNG Holdings Ltd
US$ 0.9629
(140.66%)
43.73M
TOIIWOncology Institute Inc
US$ 0.0123
(136.54%)
4.47k
AEIAlset Inc
US$ 2.10
(105.88%)
15.56M
NMRANeumora Therapeutics Inc
US$ 1.90
(-82.08%)
882.43k
BDMDBaird Medical Investment Holdings Ltd
US$ 4.82
(-36.58%)
336.99k
SIDUSidus Space Inc
US$ 3.21
(-34.49%)
2.07M
AIPArteris Inc
US$ 8.01
(-21.39%)
51
MARXMars Acquisition Corporation
US$ 7.35
(-21.39%)
46.53k
CMCTCreative Media and Community Trust Corporation
US$ 0.3025
(34.44%)
44.92M
CGBSCrown LNG Holdings Ltd
US$ 0.9629
(140.66%)
43.73M
SVMHSRIVARU Holding Ltd
US$ 0.0463
(9.98%)
35.41M
REVBRevelation Biosciences Inc
US$ 1.12
(142.95%)
30.02M
ALCEAlternus Clean Energy Inc
US$ 1.60
(103.61%)
20.78M

VNDA Discussion

Ver más
eyeownu eyeownu 1 mes hace
im a buyer at 5.07.nice triangle has formed. low float. plenty of cash on balance sheet. book value 9.20/sh
👍️0
Zilla Zilla 3 meses hace
WOW talk about being lucky. Bought calls Friday for 2025 just in case something happens in 2024. Up 20% pre-market with an 8 all cash offer on the table.
👍️0
Monksdream Monksdream 4 meses hace
VNDA under $7
👍️0
harry crumb harry crumb 6 meses hace
Watching this closely
👍️0
Monksdream Monksdream 6 meses hace
VNDA under $10
👍️0
Monksdream Monksdream 7 meses hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 7 meses hace
Over $6
👍️0
tw0122 tw0122 7 meses hace
Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
👍️0
harry crumb harry crumb 8 meses hace
Gonna be a winner. Patience
👍️0
harry crumb harry crumb 8 meses hace
Over 5$!
👍️0
Monksdream Monksdream 8 meses hace
VNDA under $5
👍️0
harry crumb harry crumb 8 meses hace
Let er rip $$$$$$$$
👍️0
Tiger Money Tiger Money 8 meses hace
Agreed. This could double quickly
👍️0
philaya philaya 8 meses hace
got this today...
very good trades.
👍️0
harry crumb harry crumb 9 meses hace
This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
👍️0
morokoy morokoy 9 meses hace
Shares Outstanding 57,537,499 shares
Insider Shares 7,908,897 shares
Insider Ownership 13.75 %
Total Insiders 34
👍️0
morokoy morokoy 9 meses hace
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

Guess we'll have to wait on the promised 8K.

Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
👍️0
harry crumb harry crumb 9 meses hace
Minimum 8$ imo
👍️0
MiamiGent MiamiGent 9 meses hace
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
REUTERS
1 mins ago
April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
👍️0
Monksdream Monksdream 9 meses hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️ 1
MiamiGent MiamiGent 9 meses hace
Probably...but I took it at 5.49
👍️0
Monksdream Monksdream 9 meses hace
Will it grow legs after 9:30
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA Vol picking up..

$5.49 +$1.44 (+35.56%)

Volume 3,354,569

90 DAV... 2M
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA Here we go
$5.3781 +$1.3281 (32.79%)

Bid ARCX
5.36 x 10
Ask XNMS
5.38 x 11
Volume
2,971,106
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA Vol is good. Already @ 90 DAV
Volume 2,056,421
10/90-day avg. volume
7M / 2M
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA Good post, Laster.
https://www.futurepak.com/
👍️0
Laster Laster 9 meses hace
The major question is who is Future Pak really?
Is this a legit offer?
Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
Large short position. Lots of selling PM at $5.
Market does not seem to believe this offer. Sorry.
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA Float 52.05M

Shares Short (3/28/2024) 2.49M
Short Ratio (3/28/2024) 2.78
Short % of Float (3/28/2024) 5.45%
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA
Bid EDGX
4.85 x 3
Ask EDGX
4.88 x 3

Volume
1,790,654
Avg Vol (10 day) 6.63M
👍️0
MiamiGent MiamiGent 9 meses hace
Vanda Pharmaceuticals
Closed .01 (-0.25%)

Pre-market
$5.15 +1.10 (+27.16%)
As of Apr-17-2024 7:23:52 AM ET
Bid x size $5.14 x 1
Ask x size $5.16 x 3
👍️0
MiamiGent MiamiGent 9 meses hace
VNDA In 5.12. Let's see, said the blind man.
👍️0
MiamiGent MiamiGent 9 meses hace
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
👍️0
MiamiGent MiamiGent 9 meses hace
What's the news?
👍️0
Awl416 Awl416 9 meses hace
Damn
👍️0
Monksdream Monksdream 9 meses hace
Will it grow legs after 9:30
👍️0
Monksdream Monksdream 9 meses hace
Will it grow legs after 9:30
👍️0
tknuncle tknuncle 11 meses hace
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
👍️0
weedtrader420 weedtrader420 11 meses hace
FDA Approve
👍️0
Triple nickle Triple nickle 1 año hace
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 3 años hace
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
👍️0
RNsidersbuying RNsidersbuying 4 años hace
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
👍️0
XenaLives XenaLives 4 años hace
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
👍️0
Peepson Peepson 4 años hace
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
👍️0
XenaLives XenaLives 4 años hace
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

👍️0
otcmoneydoubler otcmoneydoubler 4 años hace
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
👍️0
Peepson Peepson 4 años hace
Yo, does anyone still follow this board. I might have some interesting dd to share.
👍️0
bezen bezen 8 años hace
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
👍️0
Coz Mabluda Coz Mabluda 8 años hace
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



👍️0
stocktrademan stocktrademan 8 años hace
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

👍️0
ClearlyStocks ClearlyStocks 8 años hace
VNDA $16.74
👍️0

Su Consulta Reciente

NASDAQ
VNDA
Vanda Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados